Cor Vasa 2022, 64(Suppl. 4):39-47

The year in cardiovascular medicine 2021: interventional cardiology

Javier Escaned1*, Farouc A. Jaffer2, Julinda Mehilli3, Roxana Mehran4
1 Hospital Clínico San Carlos IDISCC, Complutense University of Madrid, Madrid, Spain
2 Cardiology Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
3 Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, Klinikum der Universitaet München, Ludwig-Maximilians- -Universitaet and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
4 The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Received Date: 28 November 2021; Revision received Date: 09 December 2021; Accepted Date: 13 December 2021
Reproduced from: Escaned J, Jaffer FA, Mehilli J, Mehran R. The year in cardiovascular medicine 2021: interventional cardiology. Eur Heart J 2022;43:377–386. https://doi.org/10.1093/eurheartj/ehab884, by permission of Oxford University Press on behalf of the European Society of Cardiology

Since last year’s report in the European Heart Journal, we have witnessed substantial progress in all aspects of interventional cardiology. Of note, the practice of interventional cardiology took place amidst successive waves of the COVID-19 pandemic, which continues to be a major burden for all healthcare professionals around the globe. In our yearly review, we shall revisit the developments in percutaneous coronary intervention (PCI), structural heart interventions, and adjunctive pharmacotherapy.

Keywords: Interventional cardiology; Coronary interventions; Transcatheter aortic valve implantation; Antiplatelet agents

Received: December 20, 2022; Accepted: December 20, 2022; Published: December 30, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Escaned J, Jaffer FA, Mehilli J, Mehran R. The year in cardiovascular medicine 2021: interventional cardiology. Cor Vasa. 2022;64(Suppl. 4):39-47.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Piróth Z, Boxma-de Klerk BM, Omerovic E, Andréka P, Fontos G, Fülöp G, et al. The natural history of nonculprit lesions in STEMI: an FFR substudy of the compare-acute trial. JACC Cardiovasc Interv 2020;13: 954-961. Go to original source... Go to PubMed...
    2. Sheth T, Pinilla-Echeverri N, Moreno R, Wang J, Wood DA, Storey RF, et al. Nonculprit lesion severity and outcome of revascularization in patients with STEMI and multivessel coronary disease. J Am Coll Cardiol 2020;76: 1277-1286. Go to original source... Go to PubMed...
    3. Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, et al. Multivessel PCI guided by FFR or angiography for myocardial infarction. N Engl J Med 2021;385: 297-308. Go to original source... Go to PubMed...
    4. Denormandie P, Simon T, Cayla G, Steg PG, Montalescot G, Durand-Zaleski I, et al. Compared outcomes of ST-Elevation myocardial infarction patients with multivessel disease treated with primary percutaneous coronary intervention and preserved fractional flow reserve of non-culprit lesions treated conservatively and of those with low fractional flow reserve managed invasively: insights from the FLOWER MI trial. Circ Cardiovasc Interv 2021;14:e011314. Go to original source... Go to PubMed...
    5. Cerrato E, Mejía-Rentería H, Dehbi HM, Ahn J-M, Cook C, Dupouy P, et al. Revascularization deferral of nonculprit stenoses on the basis of fractional flow reserve: 1-year outcomes of 8,579 patients. JACC Cardiovasc Interv 2020;13: 1894-1903. Go to original source... Go to PubMed...
    6. Montone RA, Niccoli G, Crea F, Jang I-K. Management of non-culprit coronary plaques in patients with acute coronary syndrome. Eur Heart J 2020;41: 3579-3586. Go to original source...
    7. Banning AP, Serruys P, De Maria GL, Ryan N, Walsh S, Gonzalo N, et al. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study. Eur Heart J 2021. https://doi.org/10.1093/eurheartj/ehab703 Go to original source... Go to PubMed...
    8. Fearon WF, Zimmermann FM, De Bruyne B, Piroth Z, van Straten AHM, Szekely L, et al. Fractional flow reserve-guided PCI as compared with coronary bypass surgery. N Engl J Med 2021. https://doi.org/10.1056/NEJMoa2112299. Published online ahead of print. Go to original source... Go to PubMed...
    9. Takahashi K, Serruys PW, Fuster V, Farkouh ME, Spertus JA, Cohen DJ, et al. Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. Lancet 2020;396: 1399-1412. Go to original source... Go to PubMed...
    10. Hara H, Takahashi K, van Klaveren D, Wang R, Garg S, Ono M, et al. Sex differences in all-cause mortality in the decade following complex coronary revascularization. J Am Coll Cardiol 2020;76: 889-899. Go to original source... Go to PubMed...
    11. Kawashima H, Serruys PW, Ono M, Hara H, O'Leary N, Mack MJ, et al. Impact of optimal medical therapy on 10-year mortality after coronary revascularization. J Am Coll Cardiol 2021;78: 27-38. Go to original source... Go to PubMed...
    12. Madhavan MV, Howard JP, Naqvi A, Ben-Yehuda O, Redfors B, Prasad M, et al. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J 2021;42: 2643-2654. Go to original source... Go to PubMed...
    13. Romaguera R, Salinas P, Gomez-Lara J, Brugaletta S, Gómez-Menchero A, Romero MA, et al. Amphilimus- versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (SUGAR trial). Eur Heart J 2021:hab395.
    14. Jeger RV, Farah A, Ohlow M-A, Mangner N, Möbius-Winkler S, Weilenmann D, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet 2020;396: 1504-1510. Go to original source... Go to PubMed...
    15. Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J 2020;41: 3715-3728. Go to original source... Go to PubMed...
    16. Hildick-Smith D, Egred M, Banning A, Brunel P, Ferenc M, Hovasse T, et al. The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN). Eur Heart J 2021;42: 3829-3839. Go to original source... Go to PubMed...
    17. Jaffer FA, Mehilli J, Escaned J. Left main coronary disease at the bifurcation: should the pendulum swing back towards the provisional stenting approach? Eur Heart J 2021;42: 3840-3843. Go to original source... Go to PubMed...
    18. Ybarra LF, Rinfret S, Brilakis ES, Karmpaliotis D, Azzalini L, Grantham JA, et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies CTO-arc consensus recommendations. Circulation 2021;143:479-500. Go to original source... Go to PubMed...
    19. Wu EB, Brilakis ES, Mashayekhi K, Tsuchikane E, Alaswad K, Araya M, et al. Global chronic total occlusion crossing algorithm: JACC state-of-the-art review. J Am Coll Cardiol 2021;78:840-853. Go to original source... Go to PubMed...
    20. Beohar N, Kaltenbach LA, Wojdyla D, Pineda AM, Rao SV, Stone GW, et al. Trends in usage and clinical outcomes of coronary atherectomy: a report from the national cardiovascular data registry CathPCI registry. Circ Cardiovasc Interv 2020;13:e008239. Go to original source... Go to PubMed...
    21. Kinnaird T, Gallagher S, Sharp A, Protty M, Salim T, Ludman P, et al. Operator volumes and in-hospital outcomes: an analysis of 7,740 rotational atherectomy procedures from the BCIS national database. JACC Cardiovasc Interv 2021;14:1423-1430. Go to original source... Go to PubMed...
    22. Hill JM, Kereiakes DJ, Shlofmitz RA, Klein AJ, Riley RF, Price MJ, et al. Intravascular lithotripsy for treatment of severely calcified coronary artery disease. J Am Coll Cardiol 2020;76:2635-2646. Go to original source... Go to PubMed...
    23. Collison D, Didagelos M, Aetesam-ur-Rahman M, Copt S, McDade R, McCartney P, et al. Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). Eur Heart J 2021;42:4656-4668. Go to original source... Go to PubMed...
    24. Hong S-J, Mintz GS, Ahn C-M, Kim J-S, Kim B-K, Ko Y-G, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation: 5-year follow-up of the IVUS-XPL randomized trial. JACC Cardiovasc Interv 2020;13: 62-71. Go to original source... Go to PubMed...
    25. Xu B, Tu S, Song L, Jin Z, Yu B, Fu G, et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. Lancet 2021;398:2149-2159. Go to original source... Go to PubMed...
    26. Shishikura D, Kataoka Y, Di Giovanni G, Takata K, Scherer DJ, Andrews J, et al. Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events. Eur Heart J 2020;41:2965-2973. Go to original source... Go to PubMed...
    27. Stone GW, Maehara A, Ali ZA, Held C, Matsumura M, Kjøller-Hansen L, et al. Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque. J Am Coll Cardiol 2020;76:2289-2301. Go to original source... Go to PubMed...
    28. Kedhi E, Berta B, Roleder T, Hermanides RS, Fabris E, IJsselmuiden AJJ, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. Eur Heart J 2021;42: 4671-4679. Go to original source... Go to PubMed...
    29. Thiele H, Kurz T, Feistritzer H-J, Stachel G, Hartung P, Eitel I, et al. Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. Eur Heart J 2020;41: 1890-1899. Go to original source... Go to PubMed...
    30. Tamburino C, Bleiziffer S, Thiele H, Scholtz S, Hildick-Smith D, Cunnington M, et al. Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: SCOPE 2 randomized clinical trial. Circulation 2020;142:2431-2442. Go to original source... Go to PubMed...
    31. Möllmann H, Holzhey DM, Hilker M, Toggweiler S, Schäfer U, Treede H, et al. The ACURATE neo2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes. Clin Res Cardiol 2021;110:1912-1920. Go to original source... Go to PubMed...
    32. Lansky AJ, Makkar R, Nazif T, Messé S, Forrest J, Sharma R, et al. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve Implan Tation: the REFLECT I trial. Eur Heart J 2021;42:2670-2679. Go to original source... Go to PubMed...
    33. Nazif TM, Moses J, Sharma R, Dhoble A, Rovin J, Brown D, et al. Randomized evaluation of TriGuard 3 cerebral embolic protection after transcatheter aortic valve replacement: REFLECT II. JACC Cardiovasc Interv 2021;14:515-527. Go to original source... Go to PubMed...
    34. Leclercq F, Robert P, Akodad M, Macia J-C, Gandet T, Delseny D, et al. Prior balloon valvuloplasty versus direct transcatheter aortic valve replacement: results from the DIRECTAVI trial. JACC Cardiovasc Interv 2020;13:594-602. Go to original source... Go to PubMed...
    35. Jørgensen TH, Thyregod HGH, Ihlemann N, Nissen H, Petursson P, Kjeldsen BJ, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J 2021;42:2912-2919. Go to original source... Go to PubMed...
    36. Bleiziffer S, Simonato M, Webb JG, Rodés-Cabau J, Pibarot P, Kornowski R, et al. Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. Eur Heart J 2020;41:2731-2742. Go to original source... Go to PubMed...
    37. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al., 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2021:ehab395. doi:10.1093/eurheartj/ehab395 Go to original source... Go to PubMed...
    38. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med 2021;385:1643-1655. Go to original source... Go to PubMed...
    39. Watanabe. STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome. Eur Heart J 2021.
    40. Giacoppo D, Matsuda Y, Fovino LN, D'Amico G, Gargiulo G, Byrne RA, et al. Short dual antiplatelet therapy followed by P2Y12inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2021;42:308-319. Go to original source... Go to PubMed...
    41. Kirtane AJ, Stoler R, Feldman R, Neumann F-J, Boutis L, Tahirkheli N, et al. Primary results of the EVOLVE short DAPT study: evaluation of 3-month dual antiplatelet therapy in high bleeding risk patients treated with a bioabsorbable polymer-coated everolimus-eluting stent. Circ Cardiovasc Interv 2021;14(3):e010144. Go to original source... Go to PubMed...
    42. Mehran R, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, et al. 3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation. JACC Cardiovasc Interv 2021;14:1870-1883. Go to original source... Go to PubMed...
    43. Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J 2021;42:4624-4634. Go to original source... Go to PubMed...
    44. Kim CJ, Park M-W, Kim MC, Choo E-H, Hwang B-H, Lee KY, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet 2021;398:1305-1316. Go to original source... Go to PubMed...
    45. Koo B-K, Kang J, Park KW, Rhee T-M, Yang H-M, Won K-B, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021;397:2487-2496. Go to original source... Go to PubMed...
    46. Montalescot G. Anti-thrombotic strategy to lower all cardiovascular and neurologic ischemic and hemorrhagic events after trans-aortic valve implantation for aortic stenosis-ATLANTIS. American College of Cardiology Virtual Annual Scientific Session (ACC 2021). 2021.
    47. Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020;382:120-129. Go to original source... Go to PubMed...
    48. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;382:1696-1707. Go to original source... Go to PubMed...
    49. Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, et al. Edoxaban versus vitamin k antagonist for atrial fibrillation after TAVR. N Engl J Med 2021;385:2150-2160. Go to original source... Go to PubMed...
    50. Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, et al. Diagnostic performance of in-procedure angiography-derived quantitative flow reserve compared to pressure-derived fractional flow reserve: the FAVOR II Europe-Japan study. J Am Heart Assoc 2018;7:e009603. Go to original source... Go to PubMed...
    51. Garot P, Iriart X, Aminian A, Kefer J, Freixa X, Cruz-Gonzalez I, et al. Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: rationale and design of the PREDICT-LAA study. Open Heart 2020;7:e001326. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes